BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.
BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.
Stock Performance
BetterLife Pharma Inc. News 29 articles
- BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
- BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
- BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
- BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
- BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
- BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
- US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
- BetterLife Pharma to Host Investors Update Call on September 18, 2023
- BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
- BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
- BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
- BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
- BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
- BetterLife Continues Progress on BETR-001 IND-Enabling Studies
- BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
- BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
- Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
- BetterLife Closes $1,857,143 of Private Placement
- BetterLife Files Amended and Restated Offering Document for Offering of Units
- Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
- BetterLife Announces Pricing of Proposed Offering of Units
- BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
- BetterLife Announces Closing of Private Placement
- BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
- BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
- BetterLife Lead Drug BETR-001 Promotes Structural Neural Plasticity in Preclinical Model
- BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder Treatment
- BetterLife Pharma Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
- BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC